stem cell therapy-treatment for adhd by dr alok sharma, mumbai, india
improvement seen in just 5 days after stem cell therapy treatment for Global Developmental Delay with Attention Deficit Hyperactivity Disorder predominantly Hyperactivity Disorder by dr alok...
By: Neurogen Brain and Spine Institute
Read the original:
stem cell therapy-treatment for adhd by dr alok sharma, mumbai, india - Video
Boston, MA (PRWEB) June 03, 2014
Today, Dr. James L. Sherley, the Director of Bostons Adult Stem Cell Technology Center, LLC (ASCTC) described a new technology for identification of new drug candidates that are toxic to adult stem cell cells in the human body. The new AlphaSTEM technology is the first of its kind to address a long-standing unmet need in the pharmaceutical industry.
Dr. Sherley presented the AlphaSTEM technology at the 7th Annual Massachusetts Life Sciences Innovation Day (MALSI Day 2014; http://www.mattcenter.org/malsi-day-2014/home.html) at the Harvard Club of Boston. ASCTC is one of a select number of start-up companies invited to present posters on their newest innovative biotechnologies at the all day event, which features the best and brightest life sciences innovations of the year.
Just as adult stem cells are crucial for life and normal organ function, their safety is crucial for successful treatment with new drugs. Even if a new drug has high activity against a disease or disorder; it will not be an effective treatment, if it is also too toxic to adult stem cells.
Adult stem cells are found in all renewing tissues and organs of the human body, like hair, skin, liver, and even the brain. They are responsible for replacing old mature tissue cells with new young cells. They are also essential cells for repairing injured tissues and wounds.
Some drugs are known to harm adult stem cells. Examples of these are many cancer drugs. Cancer drugs are often administered at the highest doses at which patients can tolerate the adverse effects of the drugs on adult stem cells. ASCTCs AlphaSTEM technology could accelerate discovery of better cancer drugs with less adult stem cell toxicity.
The major application proposed for the new AlphaSTEM technology is use by pharmaceutical companies to identify adult stem cell-toxic drugs before initiating clinical trials with them or entering the marketplace. Drug failure in clinical trials due to safety concerns is a major unrecovered cost of drug development. Chronic adult stem cell toxicity that now may go undetected until after marketing can result in tragic deaths for patients and catastrophic injury liabilities for the responsible drug companies. The Merck drug Vioxx is an example of such an unfortunate mishap.
The problem faced by the Food and Drug Administration (FDA) and the pharmaceutical industry is how to monitor drug effects on adult stem cells, when the cells are difficult to identify, isolate, produce, and count. The solution presented by ASCTC was a computer simulation approach based on the universal tissue cell production properties of adult stem cells.
ASCTC partnered with AlphaSTAR Corporation, a leading global provider of simulation technologies, to develop the AlphaSTEM software program that can simulate the culture multiplication of adult tissue stem cells found in any human tissue. AlphaSTEM technology not only has the power to detect drug toxicity against adult stem cells, but also against other specialized types of tissue cells specifically.
Director Sherley predicted that the introduction of AlphaSTEM technology into the pharmaceutical industry would have many immediate benefits. With relatively inexpensive detection of drugs destined to fail in expensive clinical trials, the new technology could save billions of currently wasted dollars, reducing overall drug development costs in the U.S. by as much as 20%. These savings could accelerate the rate of arrival of new effective drugs to patients by a comparable reduction in time. AlphaSTEM technology may also reduce the occurrence of drugs thought safe, but which actual have a lurking toxicity that emerges as lethal to some patients with wider and longer use.
Read more from the original source:
The Adult Stem Cell Technology Center, LLC Announces New Technology for Preventing Catastrophic Adult Stem Cell ...
Dr. Mark Penn, founder and CMO of Juventas Therapeutics
While the optimal treatment for heart failure was provided to a group of patients, they were still having symptoms. However when a new drug therapy based in regenerative medicine was given to these patients they showed clinically meaningful improvements in end systolic volumes, end diastolic volumes, ejection fraction and NTproBNP levels.
The drug, produced by Cleveland, Ohio-based Juventas Therapeutics, called JVS-100, is a non-viral gene therapy that expresses SDF-1 and promotes endogenous stem cell repair of the heart in patients with severe heart failure.
"What was remarkable about the improvement is that this drug was given to patients who had heart failures stemming from heart attacks that occurred - on average- about eleven years ago," said Dr. Mark Penn, founder and CMO of Juventas Therapeutics, and director of Cardiovascular Research at Summa Health System in Akron, Ohio.
Penn presented phase II clinical data last month at the European Society of Cardiology- Heart Failure Congress in Athens, Greece.
The field of regenerative medicine, which is the process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function, has come a long way. Penn explained that 14 years ago that stem cell based repairs lacked molecular signals that orchestrated the repairs. "Doing research we asked what drives stem cell repair? We saw that newly injured tissue was sending some signal to ask for it to be repaired. And in 2000 we discovered SDF-1 could aid that signal. Now our theory is validated that the gene therapy is a key factor for recruiting stem cells to the site for any injured tissue."
The therapy showed an 80% chance of a significant decrease in mortality for high risk heart failure patients.
With this success, Penn hopes to start next summer of 2015 on a larger trial of 300-400 patients. When that trial is initiated the company will have to move from manufacturing the drug for clinic studies to a commercial scale. Once the drug has regulatory approval the company will decide where to manufacture.
When asked about the reason for the success of the company, Penn says that "the company has always been driven by data. We had no preconceived ideas that this should work. We designed good trials, looked at the data and that told us where to go."
With regard to the financial side of the business, the company has worked with venture investors. And they have formed partnerships. The company has on-going collaborative research programs with Cleveland Clinic, Center for Stem Cell & Regenerative Medicine, Global Cardiovascular Innovation Center and Summa Health System.
Follow this link:
New Drug-Based Approach to Regenerative Medicine for Heart Failure
A Littlestown resident went through a five-day procedure to give bone marrow stem cells to a man living in France
By Adam Michael
@goodoletwonames on Twitter
John Sibirtzeff will never meet the man who used his stem cells to heal. He'll never know exactly what his affliction was, and he's OK with that.
A month ago, Sibirtzeff spent five days in Washington D.C. donating bone marrow stem cells that would be used to heal a 69-year-old man living in France.
"I'll never know who the recipient was," he said. "I'll never know if he was American or French, military or non."
When Sibirtzeff, of Littlestown, was in Navy boot camp in 2007, he opted into the C.W. Bill Young Department of Defense Marrow Donor Program. Naval doctors drew a vial of his blood and stored it after identifying his type. In 2011, Sibirtzeff finished his tour of duty, but his name remained on the donor list.
This past January, the program contacted Sibirtzeff requesting that he return for testing, as he was a potential match for a 69-year-old man living in France.
According to the program's website, salutetolife.org, 70 percent of patients are unable to find a match within their families. Sibirtzeff's receiver was among them.
See the original post:
Everyday Hero: Littlestown man donates bone marrow stem cells to stranger
CC to throw soon
CC Sabathia is planning to resume throwing while standing later this week.
Sabathia, who went on the disabled list May 11 with right knee inflammation, had a cortisone and stem-cell injection in the knee soon after. He has been walking on a low-impact treadmill for several days and throwing from a chair.
"Were just taking it further each day with more and more stuff and trying to see if its going to swell up," Sabathia said Monday. "I have no pain so far, so hopefully start throwing some time this week and go from there."
Sabathia, who said he got some advice from Knicks forward Amare Stoudemire who has had a similar procedure is scheduled to return near the beginning of July.
Teix gets good news
There was some good news on Mark Teixeira (inflamed right wrist) following Monday nights loss.
Joe Girardi said doctors gave "pretty good news" on Teixeira but the manager wouldnt commit on whether the first baseman would return tonight.
Teixeira, who received a cortisone shot in the surgically repaired wrist Saturday after leaving a game with lingering pain, was hoping to see improvement today. If he doesnt, there could be cause for concern.
Beltran progressing
See the rest here:
Yanks notes: CC Sabatbia to throw soon
June 2, 2014
redOrbit Staff & Wire Reports Your Universe Online
A subtle alternation in DNA involving one single-letter change in the genetic code is enough to generate blond hair in men and women, researchers from Howard Hughes Medical Institute and the Stanford University Medical Center report in Sundays edition of the journal Nature Genetics.
According to developmental biology professor Dr. David Kingsley and his colleagues, a molecule essential to stem cell function plays a vital role in determining a persons hair color. Their analysis for the first time explains the molecular basis for one of our most noticeable physical characteristics.
This genetic mutation is the biological mechanism that helps create that [blond] color naturally, Kingsley, who is also an investigator with Howard Hughes Medical Institute, told Karen Weintraub of National Geographic News. This is a great biological example of how traits can be controlled, and what a superficial difference blond hair color really is.
He added that the study also provides new insight into how the human genome works, since this particular mutation does not impact the protein production of any of its 20,000 genes. Rather, it causes regularly darker hair to become blonde through a process Dr. Kingsley likens to a 20 percent turn of the metaphorical thermostat dial regulating a signaling gene located in the skins hair follicles, Weintraub added.
Weve been trying to track down the genetic and molecular basis of naturally occurring traits such as hair and skin pigmentation in fish and humans to get insight into the general principles by which traits evolve, Dr. Kingley said in a statement. Now we find that one of the most crucial signaling molecules in mammalian development also affects hair color.
The signaling gene in question regulates the expression of a gene that encodes KITLG, a protein that is also known as a stem cell factor. It is also involved in the formation of blood, egg, sperm and stem cells, so completely switching it on or off could have disastrous consequences. However, the mutation impacts the amount of KITLG that is expressed in the hair follicles without altering the way its expressed elsewhere in the body.
In order to discover the blond-hair DNA mutation, the study authors examined a part of the genome that had previously been associated with blondness in people from Iceland and the Netherlands, Weintraub explained. They identified the single-letter change responsible for the trait, and then tested what that alternation did by growing human skin cells in a petri dish. The cells demonstrated a reduction in activity in the switch controlling the signaling gene.
Upon introducing the change into normally brown-haired laboratory mice, the researchers observed that the coats of the rodents became significantly lighter. Furthermore, their study demonstrated that noticeable morphological effects can be observed following slight, tissue-specific changes in the expression of genes, as well as emphasizing how difficult it is to clearly link particular DNA changes with specific clinical or phenotypic outcomes.
Here is the original post:
One Slight Genetic Change Responsible For Blond Hair In Humans
stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india
after stem cell therapy treatment for mental retardation with delayed milestones by dr alok sharma, mumbai, india. Stem Cell Therapy done date 18/02/2013 Aft...
By: Neurogen Brain and Spine Institute
Read this article:
stem cell therapy - treatment for mr with delayed milestones by dr alok sharma, mumbai, india - Video
(2009-04a) David Steenblock MS DO - Bone marrow stem cell therapy
David Steenblock MS DO - Bone marrow stem cell therapy 2009-04-16 part 1 April 16, 2009 Visit the Silicon Valley Health Institute (aka Smart Life Forum) at h...
By: Silicon Valley Health Institute
Read more:
(2009-04a) David Steenblock MS DO - Bone marrow stem cell therapy - Video
NIBSC/SCIENCE PHOTO LIBRARY
Embryonic stem cells may have the ability to repair damaged tissue.
A landmark stem-cell trial is sputtering back to life two-and-a-half years after it was abandoned by the California company that started it. But it now faces a fresh set of challenges, including a field that is packed with competitors.
The trial aims to test whether cells derived from human embryonic stem cells can help nerves to regrow in cases of spinal-cord injury. It was stopped abruptly in 2011 by Geron of Menlo Park, California (see Nature 479, 459; 2011); the firm said at the time that it wanted to focus on several promising cancer treatments instead. Now, a new company Asterias Biotherapeutics, also of Menlo Park plans to resurrect the trial with a US$14.3-million grant that it received on 29May from the California Institute for Regenerative Medicine (CIRM), the states stem-cell-funding agency.
But the field has moved on since Geron treated its first patient in 2010, and the therapy that Asterias inherited is no longer the only possibility for spinal-cord injury. StemCells, a biotechnology company in Newark, California, has treated 12 patients in a safety study of a different type of stem cell, and it plans to start a more advanced trial this year to test effectiveness. And another entrant to the field, Neuralstem of Germantown, Maryland, received regulatory approval in January 2013 to begin human tests of its stem-cell product.
Gerons human trial was the first approved to use cells derived from human embryonic stem cells. But regulators halted it twice, once citing concerns about the purity and predictability of the cells being implanted, and again after the company reported seeing microscopic cysts in the spinal cords of rats that had been treated in preclinical studies. The worry was that the cysts could be teratomas uncontrolled growths that can form from embryonic stem cells, a feared side effect of treatment. Geron later said that the growths were not teratomas, and the US Food and Drug Administration allowed the trial to proceed. But after injecting the cells into five of the ten intended patients, the company said that it had run out of money for the trial.
Geron founder Michael West and former chief executive Thomas Okarma then formed Asterias, which bought Gerons stem-cell therapy last year. The company plans first to treat three patients with spinal-cord damage in the neck, using a low dose of the stem cells; it will then treat different people with higher doses to see if the therapy can restore any sensation or function in the trunk or limbs.
The five patients previously treated by Geron, whom Asterias continues to track, had cord damage at chest level. On 22May, Asterias reported that none of those five had experienced serious side effects from the treatment or developed immune responses to it.
Researchers say that the continuation of the former Geron trial is important because it uses a type of cell different from the fetus-derived ones used by StemCells and Neuralstem. Geron surgically implanted embryonic stem cells that had been coaxed in vitro to grow into immature myelinated glial cells, which insulate nerve fibres when mature. The other companies are using partially differentiated cells derived from fetal brain tissue, which might produce substances that protect surviving tissue and make new connections in the neural circuitry.
Its very good for the field, because we now have multiple cell lines being tested in very similar populations of patients, and this will help us define what is needed to make this approach work, says Martin Marsala, a neuroscientist at the University of California, San Diego, whose work has shown that Neuralstems cells can develop into working neurons and restore movement to rats with cord injuries in the neck.
View post:
Funding windfall rescues abandoned stem-cell trial
Bury cop needs 15,000 for treatment in USA
5:19pm Monday 2nd June 2014 in News By David Thomson, Reporter
A BURY police officer who suffered a devastating brain haemorrhage and stroke three years ago is trying to raise 15,000 to pay for groundbreaking stem cell treatment in America.
Gulf War veteran Joseph Duffy, aged 46, hopes that the procedure in Arizona will radically improve his mobility and help tackle a rare vascular disease which may have been responsible for his illness.
His wife Wendy, friends and relatives, are planning a series of fundraising events while the Bury-based police constable has launched his own online YouGiving page to help him reach his target.
The father-of-three joined the Army in 1986 and served in West Germany and Canada as well as in the Gulf War. He joined Greater Manchester Police in 2000.
Mr Duffy suffered a suspected heart attack in March, 2011, and a brain haemorrhage and stroke just two months later. He spent six weeks in hospital.
Mrs Duffy, aged 42, said: Joseph has severe left side weakness, struggles to walk and has been left with epilepsy. His speech gets a bit slurred when hes tired. He walks with a stick as well as a muscle stimulator, a cuff around his leg which he uses with a remote control to help his movement.
Joseph also suffers from Churgh Strauss syndrome, a rare vascular disease which attacks various parts of his body and which could have been responsible for the brain haemorrhage and stroke.
Mrs Duffy explained: We hope the treatment can be done this year. It involves liposuction and taking stem cells from the fat and putting them back into the body, to areas that have been damaged, to help repair them and to make new pathways for movement and connection.
Read this article:
Bury cop needs 15,000 for treatment in USA